Cross-sectional association between polyfluoroalkyl chemicals and cognitive limitation in the national health and nutrition examination survey

Neuroepidemiology

Volumn 40, Issue 2, 2013, Pages 125-132

  Power, Melinda C ^a   Webster, Thomas F ^b   Baccarelli, Andrea A ^a   Weisskopf, Marc G ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cognitive function; Epidemiology; National Health and Nutrition Examination Survey; Polyfluoroalkyl chemicals; Risk factor

Indexed keywords

ALKYL GROUP; ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; PERFLUOROHEXANE SULFONIC ACID; PERFLUORONONANOIC ACID; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; PERFLEXANE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; COGNITION; COGNITIVE DEFECT; CONFUSION; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; ENVIRONMENTAL EXPOSURE; FEMALE; HEALTH SURVEY; HUMAN; IN VITRO STUDY; MALE; NEUROPROTECTION; REVIEW; SELF REPORT; SENILITY; ALCOHOL CONSUMPTION; ARTICLE; DAILY LIFE ACTIVITY; EDUCATION; EXPOSURE; GLOMERULUS FILTRATION RATE; HEALTH INSURANCE; MAJOR CLINICAL STUDY; MEMORY DISORDER; MIDDLE AGED; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; POVERTY; PUBLIC HEALTH; SMOKING; SOCIAL SUPPORT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALKANESULFONIC ACIDS; CAPRYLATES; CAUSALITY; COGNITION DISORDERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; ENVIRONMENTAL EXPOSURE; FEMALE; FLUOROCARBONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITION SURVEYS; PROTECTIVE AGENTS; SULFONIC ACIDS; UNITED STATES;

EID: 84867676256     PISSN: 02515350     EISSN: 14230208     Source Type: Journal    
DOI: 10.1159/000342310     Document Type: Review

References (36)

1. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J: Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 2007; 99: 366-394.
2. Fromme H, Tittlemier SA, Volkel W, Wilhelm M, Twardella D: Perfluorinated compounds-exposure assessment for the general population in western countries. Int J Hyg Environ Health 2009; 212:239-270.
3. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ: Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome prolifer-ator-activated receptor-alpha,-beta, and-gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci 2006; 92:476-489.
4. Kaundal RK, Sharma SS: Peroxisome prolif-erator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect 2010; 23: 241-256.
5. Steenland K, Fletcher T, Savitz DA: Epide-miologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ Health Perspect 2010; 118: 1100-1108.
6. Corsini E, Avogadro A, Galbiati V, dell'Agli M, Marinovich M, Galli CL, Germolec DR: In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs). Toxicol Appl Pharmacol 2011; 250:108-116.
7. Grandjean P, Andersen EW, Budtz-Jørgensen E, Nielsen F, Mølbak K, Weihe P, Heilmann C: Serum vaccine antibody concentrations in children exposed to perfluorinat-ed compounds. JAM A 2012; 307: 391-397.
8. Harada KH, Ishii TM, Takatsuka K, Koizumi A, Ohmori H: Effects of perfluorooc tane sulfonate on action potentials and currents in cultured rat cerebellar purkinje cells. Bio-chem Biophys Res Commun 2006; 351: 240-245.
9. Liu X, Liu W, Jin Y, Yu W, Liu L, Yu H: Effects of subchronic perfluorooctane sulfonate exposure of rats on calcium-dependent signaling molecules in the brain tissue. Arch Toxi-col 2010; 84: 471-479.
10. Austin ME, Kasturi BS, Barber M, Kannan K, MohanKumar PS, MohanKumar SM: Neuroendocrine effects of perfluorooctane sulfonate in rats. Environ Health Perspect 2003; 111:1485-1489.
11. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL: Polyfluoroalkyl chemicals in the US Population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ Health Perspect 2007; 115:1596-1602.
12. Kato K, Wong LY, Jia LT, Kuklenyik Z, Calafat AM: Trends in exposure to polyfluoroalkyl chemicals in the US population: 1999-2008. Environ Sci Technol 2011; 45:8037-8045.
13. van Wijngaarden E, Winters PC, Cory-Slechta DA: Blood lead levels in relation to cognitive function in older US adults. Neu-rotoxicology 2011; 32:110-115.
14. Wechsler D: Administration and Scoring Guide, Wechsler Adult Intelligence Scale-Third Edition (WAIS-III). San Antonio, Harcourt Brace & Co, 1997.
15. Allison PD: Imputation of categorical variables with PROC MI; in SAS Institute Inc (ed): Proceedings of the Thirtieth Annual SAS® Users Group International Conference. Cary, SAS Institute Inc, 2005.
16. Nelson JW, Scammell MK, Hatch EE, Webster TF: Social disparities in exposures to bi-sphenol A and polyfluoroalkyl chemicals: a cross-sectional study within NHANES 2003-2006. Environ Health 2012; 11:10.
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
18. Korn EL, Graubard BI: Epidemiologic studies utilizing surveys: accounting for the sampling design. Am J Public Health 1991; 81: 1166-1173.
19. Nelson JW, Hatch EE, Webster TF: Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general US population. Environ Health Per-spect 2010; 118: 197-202.
20. Takacs ML, Abbott BD: Activation of mouse and human peroxisome proliferator-activat-ed receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol Sci 2007; 95:108-117.
21. Maloney EK, Waxman DJ: Trans-activation of PPAR-alpha and PPAR-gamma by structurally diverse environmental chemicals. Toxicol Appl Pharmacol 1999; 161:209-218.
22. Szekely CA, Green RC, Breitner JC, Ostbye T, Beiser AS, Corrada MM, Dodge HH, Ganguli M, Kawas CH, Kuller LH, Psaty BM, Resnick SM, Wolf PA, Zonderman AB, Welsh-Bohmer KA, Zandi PP: No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 2008; 70:2291-2298.
23. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G: A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 2011; 68:45-50.
24. Gold M, Alderton C, Zvartau-Hind M, Egg-inton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamagi U, Sawchak S: Rosi-glitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-control led phase II I st udy. Dement Geriatr Cogn Disord 2010; 30: 131-146.
25. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD: Efficacy of rosi-glitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006; 6: 246-254.
26. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13:950-958.
27. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwa-moto T: Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 2009; 57: 177-179.
28. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T: Efficacy of PPAR-7 agonist pioglitazone in mild alzheimer disease. Neurobiol Aging 2011; 32:1626-1633.
29. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256:240-246.
30. Jorm AF, Christensen H, Korten AE, Jacomb PA, Henderson AS: Memory complaints as a precursor of memory impairment in older people: a longitudinal analysis over 7-8 years. Psychol Med 2001; 31: 441-449.
31. Mitchell AJ: The clinical significance of subjective memory complaints in the diagnosis of mild cognitive impairment and dementia: a meta-analysis. Int J Geriatr Psychiatry 2008; 23: 1191-1202.
32. Miranda B, Madureira S, Verdelho A, Ferro J, Pantoni L, Salvadori E, Chabriat H, Erkin-juntti T, Fazekas F, Hennerici M, O'Brien J, Scheltens P, Visser MC, Wahlund LO, Waldemar G, Wallin A, Inzitarion D: Self-perceived memory impairment and cognitive performance in an elderly independent population with age-related white matter changes. J Neurol Neurosurg Psychiatry 2008; 79: 869-873.
33. Jonker C, Geerlings MI, Schmand B: Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 2000; 15:983-991.
34. Abdulrab K, Heun R: Subjec tive memor y i m-pairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria. Eur Psychiatry 2008; 23: 321-330.
35. Olsen GW, Burris JM, Ehresman DJ, Froeh-lich JW, Seacat AM, Butenhoff JL, Zobel LR: Half-life of serum elimination of per-fluorooctanesulfonate, perfluorohexanesul-fonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 2007; 115:1298-1305.
36. Bartell SM, Calafat AM, Lyu C, Kato K, Ryan PB, Steenland K: Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ Health Perspect 2010; 118:222-228.